ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy
ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy: Feasibility Study (CARTePRO)
Stiftung Swiss Tumor Institute
11 participants
Mar 21, 2022
OBSERVATIONAL
Conditions
Summary
This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting. ePRO assessments will be explored for their feasibility to engage in monitoring and management of CAR T-related toxicities as well as using these digital ePRO tools may improve both, its safety and accessibility.
Eligibility
Inclusion Criteria4
- Signed ICF
- Patients \> 18 years
- Patients receiving CAR T cell treatment
- Personal smartphone with iOS or Android system. The operating system must be updated to one of the two newest main versions.
Exclusion Criteria2
- Patients, whose compliance to the studies' protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted.
- Patients with insufficient knowledge about the use of a smartphone.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is an observational study using the Consilium CareTM smartphone ePRO application.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05354973